Jordi Riba
Pioneer Researcher in Ayahuasca Pharmacology (1968-2020)
Data updated
Research Footprint
Jordi Riba appears in 34 tracked papers (2001–2022), most studied alongside Ayahuasca, DMT and Psilocybin, across Depressive Disorders, Neuroimaging & Brain Measures and Healthy Volunteers.
Most-cited paper: Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (814 citations).
Frequent co-authors: Maria Barbanoj, Draulio Araújo and Marta Valle.
Background & Research
Jordi Riba was a visionary pharmacologist who led the first scientific investigations into ayahuasca in human volunteers. His seminal work at the Universitat Autònoma de Barcelona and Maastricht University demonstrated the safety and pharmacokinetics of orally active DMT and utilized neuroimaging to map the brain's response to the 'Amazonian brew.' His research laid the foundation for modern clinical science on ayahuasca.
Key Impact
Conducted the first placebo-controlled trials with ayahuasca, establishing its safety and neurophysiological impact.
Collaboration Network
46 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Jordi Riba is associated with.